Tarsus Pharmaceuticals Inc（TARS）の株式分析TARSTarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Tarsus Pharmaceuticals Inc is currently not a strong buy due to its recent price drop and negative momentum indicators. The current price is $68.20, with an RSI of 35.07 indicating oversold conditions. Despite a gross margin of 93% and a forward P/E ratio of 68.03, the stock has seen a 20-day change of -9.90% and insider selling has increased by 1503.33%, which raises concerns about the stock's near-term performance. The main risk is the upcoming earnings report on November 3, 2026, where the EPS estimate is -1.43, potentially leading to further price volatility.